Vaccination responses in lung transplant patients
Official title: Vaccination responses in lung transplant recipients
Funded at Stanford University · NIH-11406132 · Data updated 2026-11-12
This grant studies how people who have received lung transplants respond to COVID-19 vaccines and why their antibody responses may be limited.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | August 5, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $409,529 |
| NIH project number | 5U01HL163124-05 |
| Project ID | NIH-11406132 on NIH RePORTER |
Who could benefit from this research
✓Could help
Lung transplant recipients who are undergoing or have recently completed COVID-19 vaccination and are on immunosuppressive therapy.
✕Less likely to help
Patients without lung transplants or those not receiving vaccines may not benefit.
What this research studies
Lung transplant recipients are at high risk from infections, and vaccines are their best protection, but their immune systems may react differently due to immunosuppression. The project uses a system vaccinology approach to map complex immune responses after vaccination and to identify factors that influence antibody production. It aims to create a vaccination-oriented biobank and a clinical center to study how these patients respond and how to improve vaccination strategies. Researchers from Stanford, Inova-Fairfax, and Houston Methodist will collect samples and data to enable comprehensive analyses of immune responses.
Why it matters
Potential benefit: If successful, the work could lead to better vaccination approaches and personalized strategies to protect lung transplant patients from COVID-19.
How similar studies have gone: Recent studies suggest reduced antibody responses in transplant recipients, highlighting a need for deeper investigation; this project tests a comprehensive biobank approach.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Nicolls, Mark Robert — Stanford University
- Study coordinator: Nicolls, Mark Robert
Related research
Other NIH-funded projects on the same topics.
-
Vaccine responses in people with lung transplants
This project looks at how well COVID-19 vaccines trigger immune protection in people who have had lung transplants.
-
Understanding how lung transplant recipients respond to vaccinations
This study is looking at how well lung transplant patients respond to COVID-19 vaccines, since they might not make enough antibodies, and it hopes to find better ways to protect them through improved vaccination strategies.
-
Exercise-based frailty program for people awaiting lung transplants
A tailored exercise and lifestyle program is being tested to reduce frailty and improve outcomes for people waiting for a lung transplant.
-
Understanding why a lung transplant sometimes fails early and how to tailor treatment
A study of people receiving lung transplants to find molecular differences that cause early graft failure and point to better, personalized therapies.
-
Targeting inflammation and alloimmunity in lung transplant recipients with clazakizumab
A study to see if blocking IL-6 with clazakizumab can improve survival and reduce rejection in people who have received a lung transplant.
-
The Post-Lung Transplant Aging in Immune Cells in Donor Lungs
This grant explores how aging donor lungs affect lung transplant outcomes by studying immune cells called alveolar macrophages.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.